Patent SG-11201810311W-A (SG)
Title: Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
Inventor: BON HELENE
IPC: C07K16/22
Filed: 2017-06-07
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT omit tun Hol °Holm° Ill °nom mil (10) International Publication Number WO 2017/211873 Al (51) International Patent Classification: C07K 16/22 (2006.01) A61P 11/00 (2006.01) (21) International Application Number: PCT/EP2017/063796 (22) International Filing Date: 07 June 2017 (07.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1610044.8 08 June 2016 (08.06.2016) GB (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Al- lee de la Recherche, 1070 Brussels (BE). (72) Inventors: BON, Helene; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). COMPSON, Joanne Elizabeth; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). DIXON, Kate Louise; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berk- shire SL1 3WE (GB). DOYLE, Carl Brendan; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). ELLIS, Mark; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). GOUVEIA SANCHO, Maria Margarida; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). JUPP, Ray- mond Anthony; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). KEVORKIAN, Lara; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). LIGHTWOOD, Daniel John; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). MARSHALL, Diane; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). PAYNE, Andrew Charles; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). RASTRICK, Joseph Michael David; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). SCHULZE, Moni- ka-Sarah; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). TURNER, Alison; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). TYSON, Kerry Louise; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). (74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) N co N O C (54) Title: ANTAGONIST ANTIBODIES THAT T BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS (57) : The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.